Management of haemangiomas of infancy: a retrospective analysis and a treatment protocol.
Haemangiomas of infancy are common benign endothelial neoplasms that affect roughly 1:10 children. Treatment is indicated in complicated cases. We have evaluated treatment in a multidisciplinary setting. The charts of all affected patients between 1985 and 2000 were reviewed. The personal details, complications, indications for treatment, and outcome, were evaluated. Treatment was started in 77 of the 282 cases reviewed. Ulceration and bleeding were the most common complications and were successfully treated when indicated in 29/39 patients (74%) with wound dressings and antibiotics. Systemic steroids were given to 18 patients, usually for block of the visual fields and respiratory impairment. A good or moderate result was obtained in 16/18 patients. Twelve patients required operation. Based on our results and those of others, we propose a protocol for treatment.
Bauland
Constantijn G
CG
Department of Plastic Surgery, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands. bauland@nvpc.nl
Smit
Jeroen M
JM
Ketelaars
Rein
R
Rieu
Paul N M A
PN
Spauwen
Paul H M
PH
D000402:Airway Obstruction / Q000209:etiology; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D005260:Female; D006258:Head and Neck Neoplasms / Q000150:complications / Q000628:therapy*; D006391:Hemangioma / Q000150:complications / Q000628:therapy*; D006801:Humans; D007223:Infant; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D011994:Recombinant Proteins; D012189:Retrospective Studies
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D001761:Bleomycin